1-3 of 3
Andrew L. Coveler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B049: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic  colorectal cancer (NuTide:323)

Richard H Wilson, Kristen K Ciombor, Andrew L Coveler, Janet S Graham, Benjamin L Schlechter, Thomas J George, Elena Élez, TR Jeffry Evans, Jordan Berlin, Aimery de Gramont, Fiona G McKissock, Elisabeth Oelmann, Jeffrey D Bloss, Giulia Martini, Jaafar Bennouna, Dominik P Modest, Julien Taieb, Josep Tabernero
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B049.
https://doi.org/10.1158/1535-7163.TARG-23-B049
Published: 01 December 2023
View article titled, Abstract B049: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic  colorectal cancer (NuTide:323)
Journal Articles

Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)

Khurum Khan, Uma Mukherjee, Benjamin L Schlechter, Kristen K Ciombor, Aglaia Skolariki, Andrew L Coveler, Janet S Graham, Mary Linton Peters, Stacey A Cohen, Niharika Mettu, Hélène Marijon, David Cosgrove, Fiona G McKissock, Elisabeth Oelmann, Jeffrey D Bloss, Sarah P Blagden, Aimery de Gramont, Jordan Berlin, T.R. Jeffry Evans
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B048.
https://doi.org/10.1158/1535-7163.TARG-23-B048
Published: 01 December 2023
View article titled, Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Journal Articles

Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity

Vivian Goodell, James Waisman, Lupe G. Salazar, Corazon dela Rosa, John Link, Andrew L. Coveler, Jennifer S. Childs, Patricia A. Fintak, Doreen M. Higgins, Mary L. Disis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 449–454.
https://doi.org/10.1158/1535-7163.MCT-07-0386
Published: 17 March 2008
View article titled, Level of HER-2/<em>neu</em> protein expression in breast cancer may affect the development of endogenous HER-2/<em>neu</em>-specific immunity
Open the PDF for Level of HER-2/<em>neu</em> protein expression in breast cancer may affect the development of endogenous HER-2/<em>neu</em>-specific immunity in another window